Consistent with Lou’s report that Tipe2-deficiency suppressed the DSS-associated colitis in mouse model [42], we reported that AOM/DSS-treated Tipe2 KO mice exhibited significantly less severe colitis and this might result in less severe tumorigenesis. This evidence concerns the gene TIPE2 and colitis.